Jump to ContentJump to Main Navigation

Online

249,00 € / $374.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
July 2005
ISSN:
1437-4331
DOI:
10.1515/CCLM.2005.085

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 249.00
RRP for USA, Canada, Mexico
US$ 374.00 *
Print
Individual Subscription Online only
Euro [D] 1577.00
RRP for USA, Canada, Mexico
US$ 2365.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1893.00
RRP for USA, Canada, Mexico
US$ 2838.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the International Federation of Clinical Chemistry and Laboratory Medicine and the European Federation of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Lippi, Giuseppe / Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Melichar, Bohuslav / Siest, Gérard / Whitfield, John B. / Abi Fadel, Marianne / Alvarez Menendez, Francisco V. / Azzazy, Hassan M.E. / Diamandis, Eleftherios P. / Eckardstein, Arnold / Favaloro, Emmanuel J. / Griesmacher, Andrea / Herrmann, Wolfgang / Hoffmann, Johannes J.M.L. / Hooijkaas, Herbert / Ichihara, Kiyoshi / Kaabachi, Naziha / Kim, Jeong-Ho / Korte, Wolfgang / Kroupis, Christos / Lai, Leslie Charles / Lam, Wai Kei Christopher / Marc, Janja / Miyoshi, Eiji / Özben, Tomris / Palicka, Vladimir / Panteghini, Mauro / Queralto, Jose M. / Scartezini, Marileia / Simundic, Ana-Maria / Tsongalis, Gregory J. / Wallemacq, Pierre E. / Yan, Shengkai / Young, Ian S. / Chiu, Rossa Wai Kwun / Ghosh, Debabrata / Kappelmayer, Janos / Lehmann, Sylvain / Sypniewska, Grazyna

12 Issues per year

Increased IMPACT FACTOR 2011: 2.150
Rank 10 out of 32 in category Medical Laboratory Technology in the 2011 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice

Kristiaan Wouters1 / Ronit Shiri-Sverdlov2 / Patrick J. van Gorp3 / Marc van Bilsen4 / Marten H. Hofker5

1.

2.

3.

4.

5.

Corresponding author: Marten H. Hofker, Cardiovascular Research Institute Maastricht, Department of Molecular Genetics, Universiteit Maastricht UNS50/11, P.O. Box 616, 6200MD Maastricht, The Netherlands Phone: +31-43-388-1138, Fax: +31-43-388-4574, E-mail:

Citation Information: Clinical Chemical Laboratory Medicine. Volume 43, Issue 5, Pages 470–479, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2005.085, July 2005

Publication History:
Received:
November 12, 2004
Accepted:
February 4, 2005
Published Online:
2005-07-05

Abstract

Hyperlipidemia is the most important risk factor for atherosclerosis, which is the major cause of cardiovascular disease. The etiology of hyperlipidemia and atherosclerosis is complex and governed by multiple interacting genes. However, mutations in two genes have been shown to be directly involved, i.e., the low-density lipoprotein receptor (LDLR) and apolipoprotein E (ApoE). Genetically modified mouse models have been instrumental in elucidating the underlying molecular mechanisms in lipid metabolism. In this review, we focus on the use of two of the most widely used mouse models, ApoE- and LDLR-deficient mice. After almost a decade of applications, it is clear that each model has unique strengths and drawbacks when carrying out studies of the role of additional genes and environmental factors such as nutrition and lipid-lowering drugs. Importantly, we elaborate on mice expressing mutant forms of APOE, including the APOE3Leiden ( APOE3L) and the APOE2 knock-in ( APOE2k) mouse models. These models have outstanding potential, as they are highly responsive to dietary factors and pharmacological interventions.

Keywords: apolipoprotein E (ApoE); gene targeting; genetics; genomics; hyperlipoproteinemia; low-density protein receptor (LDLR); transgenesis

Comments (0)

Please log in or register to comment.